The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer

International Journal of Gynecological Cancer

Volumn 9, Issue 2, 1999, Pages 117-122

  Schroder W ^a   Zimny, M ^a   Rudlowski, C ^a   Bull U ^a   Rath, W ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

18F FDG PET; Diagnosis; Ovarian cancer; Relapse

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPAROTOMY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0032897565     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.09903.x     Document Type: Article

References (22)

1. Warburg O. The metabolism of tumors. New York: R.R. Smith Inc., 1931:129-69.
2. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623-8.
3. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossmann HB, Fisher S. 18F-2-Deoxy-2-Fluoro-D-Glucose uptake into human tumor xenografts. Cancer 1991; 67: 1544-50.
4. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Bull U. Ergebnisse der Positronenemissionstomographie mit Fluor-18-markierter Fluordeoxyglucose bei Differentialdiagnose und Staging des Pankreaskarzinoms. Radiologe 1996; 36: 435-40.
5. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53: 331-8.
6. Hübner KF, Mcdonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18-F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993; 51: 192-4.
7. Reske SN, Bares R, Bull U, Guhlmann A, Moser E, Wannenmacher MF. Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 1996; 35: 42-52.
8. Römer W, Avril N, Dose J et al. Metabolische Charakterisierung von Ovarialtumoren mit der Positronen- Emissions-Tomographie und F-18-Fluordeoxyglukose. Fortschr Röntgenstr 1997; 166: 62-8.
9. Thigpen JT, Vance RB, Kansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559-64.
10. Schröder W, Bender HG. Pharmakologische entwicklungen zum therapeutischen Einsatz von-Biological-response-Modifiern. Gynakologe 1992; 25: 258-67.
11. Barzen G, Cordes M, Langer M, Friedmann W, Mayr AC, Felix R. Wertigkeit der Radioimmunszintigraphie im Vergleich zur Computertomographie in der Diagnostik und Verlaufskontrolle des primären Ovarialkarzinoms. Fortschr Röntgenstr 1990; 153: 85-91.
12. Jain KA, Friedmann DL, Pettinger TW, Alagappan R, Jeffrey Jr. RB, Sommer FG. Adnexal masses: Comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993; 186: 697-4.
13. 18F-Fluordeoxyglukose Positronenemissionstomographie beim Ovarialkarzinom. Methodik und erste Ergebnisse. Nuklearmedizin 1997; 36: 228-33.
14. Tahara T, Ichiya Y, Kubawara Y et al. High F-18 fluorodeoxyglucose uptake in abdominal abscesses. A PET-study. J Comput Assist Tomogr 1989; 13: 829-31.
15. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Metab 1983; 3: 1-7.
16. Hoffmann EJ, Sung-Cheng H, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979; 3: 299-308.
17. Karlan BY, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J. Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol Oncol 1993; 49: 383-8.
18. Baum RP, Hertel A, Hör G. Immunszintigraphische Diagnostik in der Nachsorge gynäkologischer Karzinome. Gynäkologe 1989; 22: 33-8.
19. Krag ND. Clinical utility of immunscintigraphy in managing ovarian cancer. J Nucl Med 1993; 34: 545-8.
20. Barzen G, Hierholzer J, Cordes M, Friedmann W, Felix R. Primary diagnosis and follow-up of ovarian cancer: Radioimmunoscintigraphy with iodine-131 labeled OC 125 monoclonal antibodies versus computed tomography and "second look". Nucl Med Biol 1991; 18: 69-76.
21. Method MW, Serafini AN, Averette HE, Rodriguez M, Penalver MA, Sevin BU. The role of radioimmunscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. Cancer 1996; 77: 2293.
22. Forstner R, Hrieuk H, Occhipinti KA, Powell CB, Frankel SD, Stern JL. Ovarian cancer: staging with CT and MR imaging. Radiology 1995; 197: 619-6.